Recent Finacing
Recent Raise
Poxel, a Lyon-based biopharma, develops oral Glimins (Imeglimin) targeting mitochondrial bioenergetics for Type 2 diabetes—Phase II monotherapy and add-on trials—and a preclinical direct AMPK activator.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
